Small volume parenteral market seen reaching $275.99 billion by 2030

The Business Research Company projects the small volume parenteral market will rise from $191.36 billion in 2025 to $275.99 billion by 2030, driven by injectable therapies, biologics and vaccine demand, and sterile drug delivery needs. North America led in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Small volume parenterals are a core sterile drug-delivery format for hospitals, surgeries and injectable treatments. - The market’s growth points to rising demand for faster, more precise and more stable delivery of medicines, vaccines and biologics. - The expansion also signals continued investment in aseptic manufacturing and sterile packaging.

What happened: - The Business Research Company published a 2026 report on the global small volume parenteral market. - The market is projected to grow from $191.36 billion in 2025 to $207.18 billion in 2026. - The report forecasts the market will reach $275.99 billion by 2030. - The report cites a 2026-to-2030 CAGR of 7.4% and a 2025-to-2026 CAGR of 8.3%. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Small volume parenterals are sterile pharmaceutical products for parenteral use, meaning they bypass the gastrointestinal tract. - These products typically come in volumes of 100 milliliters or less. - SVPs are administered through intravenous, intramuscular or subcutaneous routes. - The products are used to deliver medications, vaccines and biological treatments directly into the body. - Historical growth drivers include widespread injectable therapy use, hospital-based drug administration, glass ampule packaging, acute care treatment growth and parenteral nutrition demand. - Future growth is expected to come from biologics and vaccines, self-injectable therapies, aseptic manufacturing expansion, advanced drug delivery systems and sterile packaging investment. - Reported trends include greater use of prefilled syringes, more sterile injectables, wider use of single-dose parenterals, increased vaccine and biologic administration, and greater focus on drug safety and stability. - A free sample of the report is available here. - The full report is available here.

Between the lines: - Rising surgical volume is a major demand driver because SVPs support precise delivery of medications, electrolytes and nutrients during procedures. - The report links growth to broader healthcare shifts, including an aging population and more minimally invasive procedures. - In June 2024, the American Society of Plastic Surgeons reported a 7% rise in minimally invasive procedures in 2023, outpacing growth in traditional surgical procedures by 2%. - The same update said hand surgeries totaled 207,887 in 2023, up 2% from 2022. - The report’s regional split suggests mature demand in North America and faster adoption opportunities across Asia-Pacific.

What’s next: - The market is expected to keep expanding as biologics, vaccines and self-injectable therapies gain share. - More aseptic manufacturing capacity and sterile packaging technology investment are likely to shape competition. - Report updates now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

The bottom line: - Small volume parenterals are moving from a large market to an even larger one, with sterile injectables and advanced delivery systems driving the next leg of growth.